ABEC 4,000 Liter Single-Use Bioreactor to Expand Emergent BioSolutions Manufacturing Capability

Bethlehem, PA, USA, October 24, 2017- ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced that Emergent BioSolutions will equip their Baltimore, Maryland bulk manufacturing facility (Bayview), designated a Center for Innovation in Advanced Development and Manufacturing (CIADM), with an ABEC 4,000L CSR bioreactor. The system will be custom designed to Emergent’s process needs, operational requirements, and facility constraints, and will greatly expand cell culture capacity at the Bayview site.

ABEC Sets a New Benchmark in Single Use Bioreactor Capacity

ABEC increases the maximum capacity of its Custom Single Run (CSR®) Bioreactors to 4,000 liters, doubling the industry standard. Read more…

ABEC Introduces the Industry’s Largest Single Use Bioreactors

ABEC today announced the completion of testing and release to market of its large scale Custom Single Run™ (CSR™) Bioreactor train. The train includes a 3,500 liter working volume (4,300 liter total volume) production bioreactor, the largest single use bioreactor available in the industry.

The CSR™ Bioreactor product line can be custom engineered for any working volume in the range of 50 liters to 3,500 liters. Consistent with the key CSR™ benefit of process scalability, the 3,500 liter volume nearly doubles the current state of the art, while delivering performance comparable to stainless steel systems. In contrast, other disposable bioreactors currently on the market top out at ≤ 2,000 liters, generally with poorer mixing and mass transfer performance compared to stainless steel systems. As such, the 3,500 liter CSR™ can deliver significantly more product per square foot of floor space; a key metric in high value multiproduct biopharmaceutical manufacturing facilities.

Given ABEC’s long history in engineering systems for commercial scale manufacturing, the CSR™ Bioreactor products are also specifically designed for ease of use and high reliability. Packaging and loading of CSR™ Disposable Containers (DC’s) has been simplified for faster turnaround and lower risk of damage. Additionally, ABEC has taken steps to further reduce production risk by establishing complete in-house DC manufacturing capability with full supply chain transparency, as announced earlier this year.

Commenting on today’s announcement ABEC’s CEO Scott Pickering said: “ABEC is committed to providing complete single use, multiuse, and hybrid solutions that enable production. Our large-scale CSR™ Bioreactor capability further demonstrates ABEC’s focus on addressing shortcomings in current single use technology that have limited its adoption for commercial manufacturing.”

ABEC Begins Operations at European Centre of Excellence

Bethlehem, PA USA and Fermoy, Co. Cork, Ireland – October 8, 2015

ABEC today announced the opening of its new facility in Fermoy, Co. Cork, Ireland. ABEC acquired the 8,000m2 facility earlier this year and has completed refurbishment works and started operations. ABEC is now producing engineered process equipment for biopharmaceutical manufacturing at the site, as well as delivering direct services and support to customers in Ireland and Europe.

ABEC currently has over 50 employees at the site and continues recruitment for a range of engineering, design, manufacturing and customer support personnel. ABEC also recently completed the previously announced acquisition of Kell Stainless Ltd. in Kells, Co. Meath, bringing the total number of employees in Ireland to well over 100.

Commenting on today’s announcement ABEC’s CEO Scott Pickering said: “We are pleased to be directly serving customers from our facilities in Ireland, and would like to thank the IDA, our contractors, Co. Cork, and the people of Fermoy for their support in reaching this milestone.”

About ABEC

Since 1974, ABEC has been a global leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. A majority of the world’s pharmaceutical and biotech companies are ABEC customers; with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a custom flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. To learn more about ABEC, visit, https://www.abec.com, http://www.abecsingleuse.com, email info@abec.com and follow us on LinkedIn.

 

For more information contact:

Emily Smith, Marketing Coordinator, ABEC, esmith@abec.com, +1.610.861.4666

For employment inquiries please contact abechr@abec.com

 

ABEC to Acquire Kells Stainless Ltd. to Further Expand Global Manufacturing Capacity

Bethlehem, PA USA and Kells, Co. Meath, Ireland – May 14, 2015

ABEC today announced the signing of a definitive agreement to acquire the assets of Kells Stainless Ltd., a leading supplier of process vessels and related equipment to the biopharmaceutical industry. This acquisition will further support ABEC’s global operations and growing customer base in Ireland and Europe. Earlier this year, ABEC announced the opening of their European Headquarters and Manufacturing Centre in Fermoy, Co. Cork, which is expected to be operational in June 2015.

Kells Stainless has been in operation for over 27 years, and serves both domestic and   international   customers   from   its facility in Co.  Meath.  The  acquisition  enables  ABEC to dedicate its 8,000m2 of  new  manufacturing  space in Fermoy entirely to bioprocess  systems  assembly  and  test,  and further increases ABEC’s industry-leading capacity dedicated to biopharmaceutical manufacturing equipment.

ABEC President and CEO Scott Pickering said, “Kells Stainless has an excellent reputation in the industry for quality, integrity, and credibility, which are key core values for ABEC. Their experience and capabilities will be an asset to our global operations, and we are excited they are joining the ABEC team.

About ABEC

Since 1974, ABEC has been a global leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. A majority of the world’s pharmaceutical and biotech companies are ABEC customers; with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a custom flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. To learn more about ABEC, visit, https://www.abec.com, http://www.abecsingleuse.com, email info@abec.com and follow us on LinkedIn.

 

For more information contact:

Emily Smith, Marketing Coordinator, ABEC esmith@abec.com, +1 (610) 861-4666